Wilsons analyst Shane Storey upgraded Next Science Ltd (NXSCF – Research Report) to a Buy today and set a price target of A$0.57. The company’s shares closed last Wednesday at $0.34.
Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals Ltd., CSL, and Impedimed Limited. According to TipRanks, Storey has an average return of 10.8% and a 56.10% success rate on recommended stocks.
Next Science Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $0.36.
See the top stocks recommended by analysts >>
The company has a one-year high of $0.61 and a one-year low of $0.26. Currently, Next Science Ltd has an average volume of 6,616.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Next Science Ltd is an Australia based company formed to commercialise and develop its Xbio technology, which is a non-toxic technology with efficacy in eradicating both biofilm based and free-floating bacteria. The company’s products includes SurgX Sterile wound Gel, Bactisure Surgical Lavage and Blast X Wound Gel.
